Science · Open for opinions
Will the developer of the drug CBL-514 release new Phase 2 or 3 clinical data by November 30, 2026?
Consider publications and clinical trial announcements for the drug CBL-514 between October 9 and November 30. 79 opinions, 54% No
- Yes — 46%
- No — 54%
Deadline: November 30, 2026 at 11:59 PM UTC · 79 opinions
Resolution rules
Consider publications and clinical trial announcements for the drug CBL-514 between October 9 and November 30.
Source: www.sciencenews.org
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 09/10/2026 (00:00, horário de Brasília) até 30/11/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se a farmacêutica desenvolvedora do composto CBL-514 (Caliway) divulgar oficialmente novos dados de eficácia clínica de Fase 2 ou Fase 3 até 30/11/2026, conforme comunicado oficial no site da companhia ou registro na base ClinicalTrials.gov. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 54% of the votes: an opinion on it that turns out right earns about 46 points, a wrong one costs about 54.